Budesonide
- Generic Name
- Budesonide
- Brand Names
- Airsupra, Breyna, Breztri, Cortiment, Entocort, Pulmicort, Pulmicort Turbuhaler, Rhinocort, Symbicort, Tarpeyo, Uceris, Jorveza, Kinpeygo
- Drug Type
- Small Molecule
- Chemical Formula
- C25H34O6
- CAS Number
- 51333-22-3
- Unique Ingredient Identifier
- Q3OKS62Q6X
- Background
Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.
Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with formoterol.
- Indication
Budesonide extended release capsules are indicated for the treatment and maintenance of mild to moderate Crohn’s disease. Various inhaled budesonide products are indicated for prophylactic therapy in asthma and to reduce exacerbations of COPD. A budesonide nasal spray is available over the counter for symptoms of hay fever and upper respiratory allergies. Extended-release capsules are indicated to induce remission of mild to moderate ulcerative colitis and a rectal foam is used for mild to moderate distal ulcerative colitis. In addition, a delayed-release capsule formulation of budesonide is indicated to reduce proteinuria in adults with IgA nephropathy at risk of rapid disease progression. In Europe, budesonide is indicated to treat eosinophilic esophagitis (EoE) in adults.
- Associated Conditions
- Allergic Reaction, Allergic Rhinitis (AR), Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Collagenous Colitis, Crohn's Disease (CD), Eosinophilic Esophagitis, Exacerbation of asthma, Nasal Congestion, Nasal Polyps, Proteinuria, Pruritus, Rhino Sinusitis, Ulcerative Colitis, Vasomotor Rhinitis, Corticosteroid-responsive dermatoses, Mild Crohn’s Disease, Moderate Crohn’s Disease
- Associated Therapies
- Maintenance therapy
Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia.
- Conditions
- Infant,PrematureRespiratory Distress SyndromeBronchopulmonary Dysplasia
- Interventions
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Hospital Central "Dr. Ignacio Morones Prieto"
- Target Recruit Count
- 108
- Registration Number
- NCT03521063
- Locations
- 🇲🇽
Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosí, Mexico
Impact of Budesonide Irrigations on Patients With Chronic Rhinosinusitis and Impact on Sinus Surgery Rates
- Conditions
- Chronic Sinus CongestionChronic Sinus InfectionChronic SinusitisChronic Sinusitis - Ethmoidal, Posterior
- Interventions
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Kaiser Permanente
- Registration Number
- NCT03519061
- Locations
- 🇺🇸
Kaiser Permanante Orange County, Irvine, California, United States
Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects
- Conditions
- Acute Cellular Graft RejectionLiver Transplant Rejection
- Interventions
- First Posted Date
- 2017-10-19
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- Montefiore Medical Center
- Registration Number
- NCT03315052
Intratracheal Budesonide/Surfactant Prevents BPD
- Conditions
- Respiratory Distress SyndromeBronchopulmonary Dysplasia
- Interventions
- Drug: SalineDrug: budesonide
- First Posted Date
- 2017-09-07
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Taipei Medical University
- Target Recruit Count
- 310
- Registration Number
- NCT03275415
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- COPD ExacerbationCOPD
- Interventions
- Device: Dry Powder InhalerDevice: NebulizersDrug: BrovanaDrug: Advair DiskusDrug: PulmicortDrug: Spiriva HandiHalerDrug: Atrovent
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT03219866
- Locations
- 🇺🇸
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
The RECONSTRUCT Study - Reconstructing Disease Mechanisms in Asthma
- First Posted Date
- 2017-01-27
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Bispebjerg Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT03034005
- Locations
- 🇩🇰
Lungemedicinsk forskningsenhed, Bispebjerg Hospital, Kobenhavn, Denmark
Budesonide for Mycophenolic Acid-induced Diarrhea in Renal Transplant Recipients
- First Posted Date
- 2016-12-13
- Last Posted Date
- 2019-05-20
- Lead Sponsor
- Pooja Budhiraja, MD
- Target Recruit Count
- 9
- Registration Number
- NCT02991768
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2016-12-08
- Last Posted Date
- 2019-01-28
- Lead Sponsor
- Chiesi Farmaceutici S.p.A.
- Target Recruit Count
- 1130
- Registration Number
- NCT02986321
Clinical Study, Non Inferiority Between Noex® 32µg Versus Budecort Aqua® 32µg in Treatment of Alergic Rhinitis
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Eurofarma Laboratorios S.A.
- Registration Number
- NCT02972866
- Locations
- 🇧🇷
Allergisa pesquisa dermato-cosmética ltda, Campinas, São Paulo, Brazil
Inhaled Budesonide for Altitude Illness Prevention
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- University of Colorado, Denver
- Registration Number
- NCT02941510
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.